# Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

> **NCT00194714** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 22 (actual)

## Conditions studied

- HER2/Neu Positive
- HLA-A2 Positive Cells Present
- Stage IV Breast Cancer
- Stage IV Ovarian Cancer

## Interventions

- **BIOLOGICAL:** HER-2/neu Peptide Vaccine
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00194714
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2021-03-31
- **Final completion:** 2023-05-22
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00194714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00194714, "Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00194714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*